PMID- 14963464
OWN - NLM
STAT- MEDLINE
DCOM- 20040803
LR  - 20151119
IS  - 0955-9930 (Print)
IS  - 0955-9930 (Linking)
VI  - 16
IP  - 1
DP  - 2004 Feb
TI  - A comparative, crossover study of the efficacy and safety of sildenafil and 
      apomorphine in men with evidence of arteriogenic erectile dysfunction.
PG  - 2-7
AB  - The aim of the study was to establish and compare the efficacy and safety of 
      sildenafil and apomorphine in men with arteriogenic erectile dysfunction (ED). In 
      all, 43 men with ED and postinjection max penile systolic velocity <25 cm/s in 
      repeated Doppler ultrasonography were included. Of these, 24 men started on 
      apomorphine 2 mg and 19 on sildenafil 50 mg, the doses titrated up to 3 and 100 
      mg according to effectiveness and tolerability. Safety was evaluated according to 
      adverse events (AEs) and patient withdrawal. Efficacy was the percentage of 
      attempts resulting in erections firm enough for intercourse, based on event log 
      data. The incidence of AEs with apomorphine 3 mg was higher than with sildenafil 
      100 mg. Two men on apomorphine 3 mg discontinued treatment due to AEs. The 
      overall success rate of sildenafil was 63.7% compared to 32.1% of apomorphine 
      (Pearson chi(2), P<0.01). Of all men, 25 (58.1%) responded to sildenafil 50 mg 
      without the need for dose increase, while only one responded to apomorphine 2 mg. 
      The response to sildenafil 50 mg was age related (analysis of variance, p=0.04). 
      Satisfaction was reported by 76.75 and 13.95% of patients for sildenafil and 
      apomorphine, respectively, but 20.9% were not satisfied with any of the two 
      drugs. In conclusion, this study provides clear evidence that sildenafil, even at 
      50 mg dose, is more effective than apomorphine 3 mg in men with arteriogenic ED. 
      The fact that one out of five patients is not satisfied with the above-studied 
      drugs shows that new oral agents need to be evaluated for the treatment of this 
      disorder.
FAU - Perimenis, P
AU  - Perimenis P
AD  - Departments of Urology, University of Patras, Patras, Grece. 
      perimenis@internet.gr
FAU - Gyftopoulos, K
AU  - Gyftopoulos K
FAU - Giannitsas, K
AU  - Giannitsas K
FAU - Markou, S A
AU  - Markou SA
FAU - Tsota, I
AU  - Tsota I
FAU - Chrysanthopoulou, A
AU  - Chrysanthopoulou A
FAU - Athanasopoulos, A
AU  - Athanasopoulos A
FAU - Barbalias, G
AU  - Barbalias G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Int J Impot Res
JT  - International journal of impotence research
JID - 9007383
RN  - 0 (Dopamine Agonists)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - 0 (Vasodilator Agents)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - N21FAR7B4S (Apomorphine)
SB  - IM
MH  - Apomorphine/*administration & dosage/adverse effects
MH  - Arteries
MH  - Cross-Over Studies
MH  - Dopamine Agonists/*administration & dosage/adverse effects
MH  - Erectile Dysfunction/*drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Piperazines/*administration & dosage/adverse effects
MH  - Purines
MH  - Sildenafil Citrate
MH  - Sulfones
MH  - Treatment Outcome
MH  - Vascular Diseases/complications
MH  - Vasodilator Agents/*administration & dosage/adverse effects
EDAT- 2004/02/14 05:00
MHDA- 2004/08/04 05:00
CRDT- 2004/02/14 05:00
PHST- 2004/02/14 05:00 [pubmed]
PHST- 2004/08/04 05:00 [medline]
PHST- 2004/02/14 05:00 [entrez]
AID - 3901119 [pii]
AID - 10.1038/sj.ijir.3901119 [doi]
PST - ppublish
SO  - Int J Impot Res. 2004 Feb;16(1):2-7. doi: 10.1038/sj.ijir.3901119.